

# Monoamines and Neurosteroids in Sexual Function During Induced Hypogonadism in Healthy Men

Miki Bloch, MD; David R. Rubinow, MD; Kate Berlin, BA; Karl R. Kevala, MSC; Hee-Yong Kim, MD; Peter J. Schmidt, MD

**Context:** Although the behavioral effects of high-dose androgen administration may involve alterations in serotonergic activity, few studies have investigated the impact of androgen withdrawal on the central nervous system in humans.

**Objective:** To examine the effects of pharmacologically induced hypogonadism on several cerebrospinal fluid (CSF) systems that could mediate the behavioral concomitants of hypogonadism.

**Design:** Double-blind assessment of the effects of the short-term induction of hypogonadism and subsequent replacement with testosterone and placebo in a crossover design.

**Setting:** National Institutes of Health, Bethesda, Md.

**Participants:** Twelve healthy male volunteers.

**Interventions:** We administered the gonadotropin-releasing hormone agonist leuprolide acetate (7.5 mg intramuscularly every 4 weeks) to the healthy male volunteers, creating a hypogonadal state, and then either replaced testosterone (200 mg intramuscularly) or administered a placebo every 2 weeks for 1 month.

**Main Outcome Measures:** Mood and behavioral symptoms were monitored with daily self-ratings, and lum-

bar punctures were performed during both hypogonadal (placebo) and testosterone-replaced conditions for CSF levels of steroids and monoamine metabolites.

**Results:** The CSF testosterone, dihydrotestosterone, and androsterone levels were significantly lower during hypogonadism ( $P=.002$ ,  $.04$ , and  $.046$ , respectively), but no significant changes were observed in CSF measures of 5-hydroxyindoleacetic acid, homovanillic acid, dehydroepiandrosterone, or pregnenolone. Decreased sexual interest was observed during the hypogonadal state compared with both baseline and testosterone replacement ( $P=.009$ ) and correlated significantly with CSF measures of androsterone during both hypogonadism and testosterone replacement ( $r=-0.76$  and  $-0.81$ , respectively;  $P<.01$ ). Moreover, the change in severity of decreased sexual interest correlated significantly with the change in CSF androsterone levels between testosterone replacement and hypogonadism ( $r=-0.68$ ;  $P<.05$ ). The CSF 5-hydroxyindoleacetic acid and homovanillic acid levels did not correlate significantly with any behavioral or CSF measure.

**Conclusion:** These data suggest that the neurosteroid androsterone contributes to the regulation of sexual function in men.

*Arch Gen Psychiatry.* 2006;63:450-456

**Author Affiliations:** Behavioral Endocrinology Branch, National Institute of Mental Health (Drs Bloch, Rubinow, and Schmidt and Ms Berlin), and National Institute of Alcohol Abuse and Alcoholism (Mr Kevala and Dr Kim), National Institutes of Health, Bethesda, Md.

**R**ECENTLY, THERE HAS BEEN considerable interest in the behavioral effects of androgenic anabolic steroids, in large part due to the extent and consequences of androgenic anabolic steroid abuse among young men, the potential impact on mood and behavior of the age-related decline in androgen secretion, and the potential therapeutic use of androgen replacement in symptomatic aging men. Both increased and decreased androgen secretion have been observed to induce clinically significant mood and behavioral changes in some men.<sup>1-9</sup> However, the effects observed are not uniform, and factors have not been identified that will

predict which individuals will develop androgen-induced mood and behavioral disorders. Additionally, despite the well-described relationship between hypogonadism and loss of sexual function,<sup>10-13</sup> the hormonal mediators of the reported loss of libido are not well described.

Several physiologic systems could mediate changes in mood associated with a change in androgen secretion, including the  $\gamma$ -aminobutyric acid (GABA) and serotonin systems, both of which are involved in the control of mood and behavior and are regulated by androgens. The animal literature has clearly documented the important regulatory effects on these systems of both increases and decreases in

androgen secretion.<sup>14,15</sup> Concerted changes in androgen and serotonin may underlie behavioral disorders in humans as well. For example, Virkkunen et al<sup>16</sup> reported both lower 5-hydroxyindoleacetic acid (5-HIAA) and higher testosterone levels in the cerebrospinal fluid (CSF) of alcoholic, impulsive offenders with antisocial personality disorders compared with controls. In this study, although levels of both 5-HIAA (lower) and testosterone (higher) differed from controls in the group as a whole, higher CSF testosterone levels were associated with aggressive behavior, whereas lower 5-HIAA levels were associated with impulsive behavior. More recently, Daly et al<sup>17</sup> observed that the androgenic anabolic steroid methyltestosterone increased CSF 5-HIAA levels and that levels of CSF 5-HIAA were correlated with observed androgenic anabolic steroid-induced behavioral changes but not with CSF levels of methyltestosterone. Androgens such as testosterone and dehydroepiandrosterone (DHEA) may also influence behavior through conversion into several GABA<sub>A</sub> receptor-modulating neuroactive steroids such as androsterone, low levels of which may cause abnormalities in GABA<sub>A</sub> receptor function and mood symptoms.<sup>18</sup>

Although the serotonin system is implicated in the behavioral effects of high-dose androgen administration, those systems that mediate the effects of androgen withdrawal are less well studied. Several studies<sup>6,19-30</sup> have suggested the relevance of both declining and deficient androgen secretion and androgen withdrawal in depression that occurs in men. To identify systems that could mediate mood disturbances, behavioral symptoms related to mood (eg, sleep, appetite, energy, and impulsivity), and changes in sexual function secondary to androgen withdrawal, we examined CSF monoamine metabolites and hormone levels in healthy volunteers with no current or past psychiatric illness during gonadotropin-releasing hormone agonist (leuprolide acetate)-induced hypogonadism and testosterone replacement. Additionally, given prior findings, including those of Daly et al,<sup>17</sup> we examined correlations between observed changes in ratings of mood, behavior, and sexual function during leuprolide-induced hypogonadism and measures of CSF monoamine and hormone levels.

## METHODS

### PARTICIPANT SELECTION

This study was a component of a larger study that examined the effects on mood and behavior of gonadotropin-releasing hormone agonist-induced hypogonadism and testosterone replacement in healthy male volunteers.<sup>6</sup> Study participants were men aged 18 to 45 years (mean  $\pm$  SD age, 30.1  $\pm$  4.1 years) recruited through advertisements and referred from the National Institutes of Health Normal Volunteer Office. All were medication free, had no significant medical illness (current or in the past 2 years), and had normal laboratory results. Specifically, complete blood cell counts, blood chemistry test results (including electrolytes, liver, and kidney function tests), thyroid function test results (thyrotropin and free thyroxine), and prostate-specific antigen levels were within normal limits. Plasma total testosterone levels at baseline (mean  $\pm$  SD, 575.2  $\pm$  246.6 ng/dL [19.96  $\pm$  8.56 nmol/L]) ranged from 355 to 992 ng/dL (12.32-

34.42 nmol/L) (reference range, 300-1200 ng/dL [10.41-41.64 nmol/L]) (National Institutes of Health Clinical Center, Bethesda, Md). Plasma prolactin levels were within normal limits (1-16  $\mu$ g/L), and the mean  $\pm$  SD body mass index (calculated as weight in kilograms divided by the square of height in meters) was 25.9  $\pm$  2.3. The absence of current or past psychiatric illness was confirmed by a structured psychiatric diagnostic interview<sup>31</sup> and daily symptom self-ratings consisting of a visual analog scale<sup>32,33</sup> and the Daily Rating Form (DRF).<sup>34</sup> Participants were excluded from this study if they had a past or present psychiatric illness or evidence of persistent (>3-5 days) clinically significant mood and behavioral symptoms of moderate severity on the DRF during their 2-month screening phase. The protocol was reviewed and approved by the National Institute of Mental Health Intramural Research Board, and oral and written informed consent documents were obtained from all participants. Each of the men in the larger study was approached, and 12 agreed to participate in the lumbar puncture (LP) portion of the study. All of the men were paid for their participation in this protocol according to the guidelines of the National Institutes of Health Normal Volunteer Office.

### PROCEDURE

This was a double-blind assessment of the effects of the short-term induction of hypogonadism and subsequent replacement with testosterone and placebo in a crossover design. After a 2-month screening phase, men received leuprolide acetate (7.5 mg intramuscularly) (Lupron; TAP Pharmaceuticals, Chicago, Ill) every 4 weeks for 3 months. Leuprolide alone was administered for the first 4 weeks. Once a consistent state of hypogonadism was achieved, participants continued to take leuprolide for an additional 8 weeks and received replacement therapy under double-blind, placebo-controlled conditions. Thus, all participants received, in addition to leuprolide, testosterone enanthate (200 mg intramuscularly every 2 weeks) or placebo (sesame oil, 1.5 mL intramuscularly every 2 weeks as color-matched vehicle) for 1 month (ie, 2 consecutive injections of each compound) and then crossed over to the other replacement. The order of replacement was randomly assigned and counterbalanced. Both subjects and raters were blind to the order of replacement. Blood samples were obtained at the time of the LP. Blood samples were centrifuged, aliquoted, and stored at -70°C until time of assay.

### CSF MEASURES

All participants consumed a low-monoamine diet for 2 days before LP. The participants remained fasting from midnight. All LPs were conducted between 9:00 AM and 10:30 AM at the end of both the testosterone replacement and placebo phases. The LPs were performed with a sterile technique in the L4-L5 interspace with the participant in the lateral decubitus position. A total of 21 mL of CSF was collected from each participant. The first 3 mL collected was used for standard clinical studies. The next 18 mL was drawn in 3 aliquots (12, 3, and 3 mL). The first aliquot was subdivided into six 1-mL subaliquots and two 3-mL aliquots, to which 20  $\mu$ L of 20% formic acid was added. The samples were placed on ice and stored at -70°C until assayed.

### ASSAYS

The following CSF assays were performed: 5-HIAA, homovanillic acid (HVA), testosterone, dihydrotestosterone, androstosterone, DHEA, and pregnenolone. The CSF steroids and neurosteroids were analyzed by gas chromatography/electronic

**Table 1. Blood Hormone Levels in 12 Men During Leuprolide Acetate–Induced Hypogonadal and Testosterone-Replaced Conditions\***

	Hypogonadal	Testosterone Replaced	z Score†	P Value
Testosterone, ng/dL	44.3 (31.8)	845.9 (331.8)	3.1	.002
Free testosterone, pg/mL	3.2 (2.6)	48.5 (11.5)	3.1	.002
Estradiol, pg/mL	4.7 (1.8)	35.4 (14.2)	2.9	.003
Dihydrotestosterone, ng/dL	13.6 (7.3)	52.6 (26.8)	2.9	.003

SI conversion factors: To convert testosterone to nanomoles per liter, multiply by 0.0347; estradiol to picomoles per liter, multiply by 3.671.

\*Data are presented as mean (SD) unless otherwise indicated.

†Determined using the Wilcoxon signed rank test.

capture negative chemical ionization mass spectrometry, as described previously.<sup>35</sup> The metabolites 5-HIAA and HVA were measured using high-performance liquid chromatography with electrochemical detection.<sup>36,37</sup> Assays for 5-HIAA and HVA were performed in 1 batch, with 4% and 6% intra-assay variation, respectively.

Blood levels of testosterone, estradiol, and dihydrotestosterone were measured by radioimmunoassay as described previously,<sup>38-42</sup> and free testosterone was measured by equilibrium dialysis<sup>43</sup> (Quest Diagnostics, Baltimore, Md).

### SYMPTOM RATINGS

To assess the severity of mood symptoms, the DRF was completed at baseline and during each hormonal condition. The DRF, a 6-point Likert-type scale, was modified to include the symptoms measured in this study<sup>34</sup> and was completed nightly to represent a composite rating for the previous 12 hours; scores range from 1 (symptom not present) to 6 (symptom present in the extreme). The symptoms measured included the following: avoidance of social activity; loss of enjoyment or interest; impaired function at work or at home; irritability or anger; impaired concentration or distractibility; mood swings; feeling depressed, sad, low, or blue; anxiety or nervousness; decreased eating; increased eating; more sleep, naps, or lying in bed; low energy; loneliness or feeling rejected; being physically restless or agitated; feeling powerful, emotionally charged, or pumped up; increased sexual interest; decreased sexual interest; disturbed sleep; drinking of alcohol or use of nonprescribed drugs; impulse to hurt self; impulse to hurt someone else; acting on impulse to hurt someone; daytime hot flushes; and nighttime hot flushes. The mean DRF rating for the last 7 days of each hormonal condition was calculated for each symptom. Finally, during each biweekly clinic visit, the Beck Depression Inventory (BDI), a standardized measure of depression severity,<sup>44</sup> was completed.

### STATISTICAL ANALYSIS

Levels of both blood and CSF androgens and BDI and DRF symptom ratings were not normally distributed (ie, the standard deviation approximated the mean for several measures, and no values were negative numbers)<sup>45</sup>; consequently, all measures were compared across hormone conditions (hypogonadal vs testosterone replacement) by the Wilcoxon signed rank test.

Spearman correlation coefficients were used as a conservative measure because of the nonparametric nature of mood ratings and the skewed distribution of CSF measures. Correlations performed were those between CSF measures of steroids and monoamine metabolites and those between selected mood and behavioral symptoms and CSF measures. Spearman correlations were performed on the values for measures obtained during both the hypogonadal and testosterone-replaced conditions and on the difference in measures between these con-

ditions. However, the latter correlations were limited to only those measures (either biological or behavioral) that significantly changed across hormone conditions (as demonstrated by the Wilcoxon signed rank test). Finally, Spearman correlation coefficients were calculated between levels of free and total testosterone in the blood and levels of testosterone in the CSF.

## RESULTS

Plasma hormone levels (**Table 1**) showed significant changes between testosterone-replaced and hypogonadal conditions, with the hypogonadal state associated with significantly lower levels of total testosterone, free testosterone, dihydrotestosterone, and estradiol. Comparisons of the BDI scores and the DRF symptom scores across hormone conditions showed a significant increase (more symptomatic) in the following symptoms during the hypogonadal state compared with the testosterone-replaced condition: BDI scores ( $z=2.4$ ;  $P=.02$ ), daytime hot flushes ( $z=2.2$ ;  $P=.03$ ), nighttime hot flushes ( $z=2.2$ ;  $P=.03$ ), and decreased sexual interest ( $z=2.6$ ;  $P=.009$ ) (the symptom of increased sexual interest changed [decreased] but only at a trend level of significance [ $z=-2.0$ ;  $P=.05$ ]). The BDI scores during hypogonadism ranged from 0 to 14, but only 2 men had BDI scores of 7 or greater (values of 9 and 14). No other symptom rating scores significantly changed across hormone conditions. A similar pattern of symptom change was observed in a larger study of men participating in this protocol<sup>6</sup> (many of whom did not undergo LP).

The CSF monoamine and neurosteroid levels are presented in **Table 2**. Significantly lower CSF levels of testosterone, androsterone, and dihydrotestosterone but not DHEA or pregnenolone were observed during hypogonadism compared with the testosterone-replaced condition. No significant differences in CSF measures of 5-HIAA or HVA were observed across hormonal conditions.

### CORRELATIONS BETWEEN SYMPTOMS AND CSF MEASURES

The CSF levels of androsterone were correlated with the severity of decreased sexual interest during both hypogonadal and testosterone-replaced conditions ( $r=-0.76$ ,  $P<.01$ ; and  $r=-0.81$ ,  $P<.001$ , respectively) (**Table 3**). Additionally, the change in CSF androsterone levels was correlated with the change in the severity of decreased sexual interest between testosterone-replaced and hypogonadal conditions ( $r=-0.68$ ;  $P<.05$ ). Only a few addi-

**Table 2. Cerebrospinal Fluid Measures of Monoamine Metabolites and Neurosteroids in 12 Men During Leuprolide Acetate–Induced Hypogonadism and After Testosterone Replacement\***

Hormone	Hypogonadism	Testosterone Replaced	z Score†	P Value
5-HIAA, pmol/mL	149.1 (59.1)	137.3 (45.7)	−0.9	.39
HVA, pmol/mL	257.2 (105.5)	229.0 (78.2)	−0.9	.35
Testosterone, pg/mL	9.8 (4.8)	143.3 (63.9)	3.1	.002
Androsterone, pg/mL	20.8 (34.4)	41.1 (27.5)	2.1	.04
Dihydrotestosterone, pg/mL	0.3 (1.2)	3.7 (5.2)	2.0	.046
DHEA, pg/mL	328.5 (181.6)	366.0 (370.6)	0.0	>.99
Pregnenolone, pg/mL	11.1 (8.4)	16.8 (15.1)	1.2	.24

Abbreviations: DHEA, dehydroepiandrosterone; 5-HIAA, 5-hydroxyindoleacetic acid; HVA, homovanillic acid.

SI conversion factors: To convert testosterone and DHEA to nanomoles per liter, multiply by 3.47.

\*Data are presented as mean (SD) unless otherwise indicated.

†Determined using the Wilcoxon signed rank test.

**Table 3. Spearman Correlation Coefficients Between Cerebrospinal Fluid Measures of Neurosteroids and Symptom Ratings**

	Androsterone	Dihydrotestosterone	Testosterone
Hypogonadism			
Androsterone	1.00		
Dihydrotestosterone	0.50	1.00	
Testosterone	0.01	0.10	1.00
Beck Depression Inventory	−0.12	−0.41	−0.72*
Hot flushes (day)	−0.24	−0.32	−0.79*
Hot flushes (night)	−0.28	−0.32	−0.83*
Decreased sexual interest	−0.76*	−0.50	−0.02
Testosterone replaced			
Androsterone	1.00		
Dihydrotestosterone	0.36	1.00	
Testosterone	0.60	0.40	1.00
Beck Depression Inventory	−0.11	−0.02	0.02
Hot flushes (day)	−0.08	0.49	0.08
Hot flushes (night)	−0.30	0.44	0.20
Decreased sexual interest	−0.81*	−0.26	−0.49
Change from hypogonadism to testosterone replaced			
Androsterone	1.00		
Dihydrotestosterone	0.67*	1.00	
Testosterone	0.15	0.27	1.00
Beck Depression Inventory	0.13	−0.08	0.30
Hot flushes (day)	0.04	0.22	0.31
Hot flushes (night)	0.14	0.27	0.22
Decreased sexual interest	−0.68*	−0.46	0.04

\* $P < .05$ .

tional symptom correlations were significant. During the hypogonadal state, values of CSF testosterone significantly correlated with BDI scores ( $r = -0.72$ ;  $P = .01$ ), as well as with both daytime and nighttime hot flushes ( $r = -0.72$  and  $-0.83$ , respectively;  $P < .01$ ). No other significant correlations were observed between those symptoms selected for showing a significant difference across hormone conditions and measures of CSF monoamines or neurosteroid levels.

#### CORRELATIONS BETWEEN BLOOD HORMONE LEVELS AND CSF MEASURES

The change in serum levels of free testosterone but not total testosterone correlated with the change in CSF testosterone ( $r = 0.6$ ;  $P < .05$ ); no significant correlations were

observed, however, between these measures during either the hypogonadal or testosterone-replaced conditions.

#### CORRELATIONS BETWEEN INDIVIDUAL CSF MEASURES

The CSF measures of 5-HIAA and HVA were significantly correlated during both the leuprolide-induced hypogonadism ( $r = 0.85$ ;  $P < .01$ ) and testosterone-replaced conditions ( $r = 0.87$ ;  $P = .001$ ). Additionally, during the hypogonadal state, CSF measures of androsterone were correlated with both CSF 5-HIAA ( $r = -0.60$ ;  $P = .05$ ) and CSF DHEA ( $r = 0.66$ ;  $P < .05$ ). During testosterone replacement, there were no significant correlations other than that between 5-HIAA and HVA. However, across hormone conditions, a significant correlation

was present between changes in CSF dihydrotestosterone and androsterone ( $r=0.67$ ;  $P<.05$ ).

## COMMENT

This study yielded 2 main findings. First, the symptom of decreased sexual interest correlated significantly with CSF measures of androsterone. Thus, this novel hormone, whose affinity is low for the androgen receptor (AR) but high for the GABA<sub>A</sub> receptor, could mediate the effects of androgen on male sexual function. Second, during hypogonadism, changes in mood, sexual interest, and hot flushes were not correlated with CSF 5-HIAA or HVA. In contrast to previous studies in both animals and humans, levels of these monoamine metabolites did not significantly change during hypogonadism compared with testosterone replacement.

The short-term suppression of androgen secretion is associated with decreased libido and the development of hot flushes in most men and with changes in mood, energy level, and cognition in only some men.<sup>6,12,46</sup> In a relatively small sample of men with leuprolide-induced hypogonadism, we observed that hypogonadism was associated with a significant decrease in sexual interest and an increase in both hot flushes (daytime and nighttime) and BDI scores (depression). These data are consistent with observations from the larger cohort of men, from which the men in this study were recruited.<sup>6</sup> The symptom of decreased sexual interest did not correlate with CSF measures of testosterone, dihydrotestosterone, or DHEA, all of which are reported to increase sexual interest when administered to hypogonadal men.<sup>10,11,47</sup> However, we observed that decreased sexual interest significantly correlated with CSF measures of androsterone. The correlations with CSF androsterone were observed during both the hypogonadal and testosterone-replaced conditions; in addition, the magnitude of the decrease in sexual interest correlated with the magnitude of the decrease in CSF androsterone levels across conditions. Thus, regardless of the hormonal state, the association between decreased sexual interest and CSF androsterone levels (but not other androgens measured) remained significant. Our findings, then, suggest that CSF androsterone contributes to the regulation of sexual interest in men.

The neurobiologic characteristics of sexual behavior are complex, involving multiple neuroanatomical regions (eg, limbic and prefrontal reward areas), neuroregulatory systems (eg, serotonin, dopamine, and nitric oxide), and the influence of numerous contextual variables (eg, past experience and environmental cues).<sup>48-50</sup> Gonadal steroids are well-established neuromodulators and play an integral regulatory role in several aspects of sexual behavior. For example, in male sexual behavior, the AR and estrogen receptors  $\alpha$  and  $\beta$  are implicated; however, the mechanisms involved are not fully documented.<sup>49,51,52</sup> Additionally, sexual regulation in female rodents appears to involve neurosteroid metabolites of both progesterone and androgens, potentially acting through modulation of ligand-gated ion channels, mediating several important aspects of sexual behavior (eg, receptivity).<sup>49,53</sup>

Our findings with androsterone in men are not without precedent in studies of animal sexual behavior. Although less is known about the behavioral relevance of androsterone compared with other androgens, androsterone administration reverses castration-induced decreases in the sexual behavior of male zebra finches.<sup>54</sup> However, these effects of androsterone are not observed in other species of birds<sup>55,56</sup> or rodents.<sup>57</sup> Finally, androsterone reduces anxiety in male mice during sexual encounters<sup>58</sup> and therefore may indirectly modulate aspects of sexual behavior.

Androsterone (3 $\alpha$ -hydroxy-5 $\alpha$ -androstane-17-one) is a 17-ketosteroid metabolite of 5 $\alpha$ -dihydrotestosterone, and like other gonadal steroids, androsterone may exert its effects on the central nervous system through several possible mechanisms. It is a weak androgen with a lower affinity for the AR than either of its precursors, dihydrotestosterone or testosterone. Androsterone and its sulfate are also both potent neurosteroids<sup>59</sup> and modulate activity at the GABA<sub>A</sub> receptor complex with an affinity comparable to the neurosteroid allopregnanolone.<sup>60</sup> Androsterone increases GABA-activated chloride influx, with brain region-specific potentiation in the amygdala and hippocampus.<sup>61</sup> Finally, androsterone may serve as a precursor for the production of 3 $\alpha$ - and 3 $\beta$ -androstane-diol, the latter compound being an active ligand at the estrogen receptor  $\beta$  receptor.<sup>62,63</sup> Thus, androsterone has neuroregulatory potential and could regulate sexual function by its actions at the AR, the estrogen receptor, or the GABA<sub>A</sub> receptor complex. Recent studies of both estrogen receptor  $\beta$  and aromatase knockout mice have identified regulatory roles for both estradiol and its receptors in male sexual function.<sup>64-67</sup> Two observations in this study suggest that androsterone's effects on sexual function are more likely mediated through estrogen receptor than either AR or GABA<sub>A</sub> receptors. First, the lack of association between changes in sexual function and either testosterone or dihydrotestosterone is not consistent with an AR-mediated effect. Both testosterone and dihydrotestosterone are more potent agonists at the AR than androsterone, and if the effects on sexual function involved the AR, one would expect to observe greater effects on sexual function with changes in these more potent AR ligands. Second, no significant changes in anxiety accompanied the hypogonadism-related changes in either libido or androsterone levels, and therefore a role for GABA<sub>A</sub> action is unlikely.

The second finding of this study was the absence of evidence in humans that short-term induction of hypogonadism alters CSF monoamine activity. No significant changes in CSF monoamine levels were observed during hypogonadism compared with testosterone replacement, and no significant correlations were observed between CSF 5-HIAA and either CSF testosterone levels or behavioral symptoms. In fact, with the exception of a significant negative correlation between CSF androsterone and 5-HIAA, no significant correlations were observed between CSF levels of monoamines and those of testosterone, DHT, DHEA, or pregnenolone. Although CSF androgen levels significantly decreased during hypogonadism, we observed no decrease in 5-HIAA levels. The significant correlation

between 5-HIAA and androsterone levels during hypogonadism was negative, in a direction consistent with the observations of Virkkunen et al.<sup>16</sup> As a caveat, it is difficult to attribute physiologic significance to the correlations between CSF measures of androsterone and 5-HIAA or DHEA, since levels of neither 5-HIAA nor DHEA changed across hormonal conditions despite significant changes in androsterone. In contrast to the reported association of anabolic steroid-induced mood and behavioral symptoms (activation) with increased CSF 5-HIAA levels,<sup>17</sup> we observed no correlation between androgen withdrawal-related behavioral symptoms and measures of CSF 5-HIAA or HVA. There are several possible reasons for our inability to detect significant changes in CSF monoamine activity during induced hypogonadism. First, androgen withdrawal-related behavioral symptoms may be mediated by systems distinct from those implicated in the behavioral activation secondary to androgen excess (ie, serotonergic). Alternatively, CSF measures of monoamine metabolites, which represent integrated measures of central monoamine activity, may not be sufficiently sensitive to brain region-specific changes in monoamines occurring after a short-term change in endocrine state or behavior. For example, in male rats gonadectomy alters brain monoamine metabolism in a brain region-specific manner, increasing levels of HVA in the hypothalamus and brainstem and levels of 5-HIAA in the hypothalamus and striatum.<sup>68</sup> Finally, it is possible that our failure to observe significant correlations between CSF 5-HIAA and sexual behavior was due to the relatively low levels of behavioral symptoms that were observed in our sample.

Although not significantly correlated with sexual interest, CSF levels of testosterone correlated with both hot flush severity and BDI scores during the hypogonadal state, when men were symptomatic. Hot flush severity accounted for approximately 60% of the variance in BDI scores in a stepwise linear regression; therefore, BDI scores probably reflected hot flush-related symptoms of disturbed sleep or fatigue. The correlation between hot flushes and testosterone suggests that testosterone may be a direct thermoregulator or, alternatively, that testosterone levels reflect the amount of precursor available for aromatization to estrogen.

Our data suggest that the effects of testosterone on some aspects of sexual function are mediated by the neurosteroid metabolite of dihydrotestosterone, androsterone. In contrast to the other androgens measured in this study, CSF levels of androsterone alone correlated with decreased libido during both hypogonadism and testosterone replacement; in addition, the change in androsterone levels across hormone conditions was correlated with the corresponding decrease in sexual interest. The self-report rating scale that we used does not permit discrimination of changes in sexual behavior from changes in cognition or perception. As a caveat, had we studied a larger sample of men, it is possible that some of the correlations between additional CSF measures and symptoms would have met statistical significance. Future studies using larger samples of men, a more comprehensive measure of the components of sexual function, and possible measures of performance may identify a more spe-

cific role of androsterone or its metabolites in male sexual function. Finally, the failure to measure androsterone may help explain the discrepant findings in the literature regarding the role of testosterone in sexual function in men.

**Submitted for Publication:** May 20, 2005; final revision received September 28, 2005; accepted September 29, 2005.

**Correspondence:** Peter J. Schmidt, MD, National Institute of Mental Health, Building 10-CRC, Room 65340 (SE), 10 Center Dr MSC 1276, Bethesda, MD 20892-1276 (peterschmidt@mail.nih.gov).

**Funding/Support:** This study was supported by the Intramural Research Programs of the National Institutes of Health, National Institute of Mental Health, and National Institute of Alcohol Abuse and Alcoholism, Bethesda, Md.

**Acknowledgment:** We acknowledge Markku Linnoila, MD, PhD (in memoriam), for the monoamine metabolite assays; Carolyn Gibson, BSc, for assistance with data analysis; and Merry Danaceau, RN, MSNCS, for clinical assistance.

## REFERENCES

1. Su T-P, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz OM, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. *JAMA*. 1993; 269:2760-2764.
2. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. *Arch Gen Psychiatry*. 1994;51: 375-382.
3. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. *Arch Gen Psychiatry*. 2000;57:133-140.
4. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. *Am J Psychiatry*. 2003;160:105-111.
5. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. *Biol Psychiatry*. 1999; 45:254-260.
6. Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, Rubinow DR. The effects of pharmacologically induced hypogonadism on mood in healthy men. *Arch Gen Psychiatry*. 2004;61:997-1004.
7. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men: a clinical research center study. *J Clin Endocrinol Metab*. 1996;81:3578-3583.
8. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. *Arch Gen Psychiatry*. 2000;57:141-147.
9. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. *J Clin Endocrinol Metab*. 2000;85:60-65.
10. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. *J Clin Endocrinol Metab*. 2000;85:2839-2853.
11. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. *J Clin Endocrinol Metab*. 2002;87:1467-1472.
12. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. *J Clin Endocrinol Metab*. 1994;78:711-716.
13. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; The North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab*. 2003;88:2673-2681.
14. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. *Behav Brain Res*. 1999;105:53-68.
15. Franklin M, Craven RD, Cowen PJ. Effect of castration and castration with hor-

- mone replacement on the plasma prolactin responses to neuroendocrine challenge with iv mCPP in the male rat following a low tryptophan diet. *J Psychopharmacol.* 1996;10:250-253.
16. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeris K, Karonen S-L, Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. *Arch Gen Psychiatry.* 1994;51:20-27.
  17. Daly RC, Su T-P, Schmidt PJ, Pickar D, Murphy DL, Rubinow DR. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. *Arch Gen Psychiatry.* 2001;58:172-177.
  18. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. *Psychopharmacology (Berl).* 2003;165:97-110.
  19. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. *J Clin Endocrinol Metab.* 1999;84:573-577.
  20. Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. *Biol Psychiatry.* 2001;50:371-376.
  21. Seidman SN. The aging male: androgens, erectile dysfunction, and depression. *J Clin Psychiatry.* 2003;64(suppl 10):31-37.
  22. Brower KJ, Blow FC, Beresford TP, Fuelling C. Anabolic-androgenic steroid dependence. *J Clin Psychiatry.* 1989;50:31-33.
  23. Tennant F, Black DL, Voy RO. Anabolic steroid dependence with opioid-type features: letter to the editor. *N Engl J Med.* 1988;319:578.
  24. Malone DA Jr, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. *J Clin Psychiatry.* 1992;53:130-132.
  25. Brower KJ, Eliopoulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. *Am J Psychiatry.* 1990;147:510-512.
  26. Brower KJ. Withdrawal from anabolic steroids. *Curr Ther Endocrinol Metab.* 1997;6:338-343.
  27. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. *CNS Drugs.* 2005;19:571-595.
  28. Malone DA Jr, Dimeff RJ, Lombardo JA, Sample RHB. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. *Clin J Sport Med.* 1995;5:25-31.
  29. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. *Ann Clin Psychiatry.* 1999;11:223-231.
  30. Brower KJ, Blow FC, Eliopoulos GA, Beresford TP. Anabolic androgenic steroids and suicide [letter to the editor]. *Am J Psychiatry.* 1989;146:1075.
  31. Spitzer RL, Williams JB, Gibbon M, First MB. *Structured Clinical Interview for DSM-III-R, Patient Edition.* New York: Biometrics Research Dept, New York State Psychiatric Institute; 1990.
  32. Miller MD, Ferris DG. Research methodology: measurement of subjective phenomena in primary care research: the visual analogue scale. *Fam Pract Res J.* 1993;13:15-24.
  33. Luria RE. The validity and reliability of the visual analogue mood scale. *J Psychiatr Res.* 1975;12:51-57.
  34. Endicott J, Nee J, Cohen J, Halbreich U. Premenstrual changes: patterns and correlates of daily ratings. *J Affect Disord.* 1986;10:127-135.
  35. Kim YS, Zhang H, Kim HY. Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. *Anal Biochem.* 2000;277:187-195.
  36. Scheinin M, Chang WH, Kirk KL, Linnoila M. Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. *Anal Biochem.* 1983;131:246-253.
  37. Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. *Biol Psychiatry.* 1991;29:1110-1118.
  38. Furuyama S, Mayes DM, Nugent CA. A radioimmunoassay for plasma testosterone. *Steroids.* 1970;16:415-428.
  39. Abraham GE. Radioimmunoassay of plasma steroid hormones. In: Heftman E, ed. *Modern Methods of Steroid Analysis.* New York, NY: Academic Press; 1973:451-470.
  40. Abraham GE, Buster JD, Lucas LA, Corrales PC, Teller RC. Chromatographic separation of steroid hormones for use in radioimmunoassay. *Anal Lett.* 1972;5:509-517.
  41. Jiang N-S, Ryan PJ. Radioimmunoassay for estrogens: a preliminary communication. *Mayo Clin Proc.* 1969;44:461-465.
  42. Ito T, Horton R. Dihydrotestosterone in human peripheral plasma. *J Clin Endocrinol Metab.* 1970;31:362-368.
  43. Vermeulen A, Stoica T, Verdonck L. The apparent free testosterone concentration, an index of androgenicity. *J Clin Endocrinol Metab.* 1971;33:759-767.
  44. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry.* 1961;4:561-571.
  45. Glantz SA. *Primer of Biostatistics.* 5th ed. New York, NY: McGraw-Hill; 2001.
  46. Cherrier MM, Rose AL, Higoano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. *J Urol.* 2003;170:1808-1811.
  47. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. *Psychoneuroendocrinology.* 2000;25:53-68.
  48. Pfaus JG, Kippin TE, Centeno S. Conditioning and sexual behavior: a review. *Horm Behav.* 2001;40:291-321.
  49. Pfaus JG. Neurobiology of sexual behavior. *Curr Opin Neurobiol.* 1999;9:751-758.
  50. Bancroft J. Central inhibition of sexual response in the male: a theoretical perspective. *Neurosci Biobehav Rev.* 1999;23:763-784.
  51. Ogawa S, Chester AE, Curtis Hewitt S, Walker VR, Gustafsson J-A, Smithies O, Korach KS, Pfaff DW. Abolition of male sexual behaviors in mice lacking estrogen receptors  $\alpha$  and  $\beta$  ( $\alpha\beta$ ERKO). *Proc Natl Acad Sci U S A.* 2000;97:14737-14741.
  52. O'Donnell L, Robertson KM, Jones ME, Simpson ER. Estrogen and spermatogenesis. *Endocr Rev.* 2001;22:289-318.
  53. Frye CA. The role of neurosteroids and non-genomic effects of progestins and androgens in mediating sexual receptivity of rodents. *Brain Res Brain Res Rev.* 2001;37:201-222.
  54. Harding CF, Sheridan K, Walters MJ. Hormonal specificity and activation of sexual behavior in male zebra finches. *Horm Behav.* 1983;17:111-133.
  55. Adkins EK. Effects of diverse androgens on the sexual behavior and morphology of castrated male quail. *Horm Behav.* 1977;8:201-207.
  56. Pietras RJ, Wenzel BM. Effects of androgens on body weight, feeding, and courtship behavior in the pigeon. *Horm Behav.* 1974;5:280-302.
  57. Parrott RF. Aromatizable and  $5\alpha$ -reduced androgens: differentiation between central and peripheral effects on male rat sexual behavior. *Horm Behav.* 1975;6:99-108.
  58. Aikey JL, Nyby JG, Anmuth DM, James PJ. Testosterone rapidly reduces anxiety in male house mice (*Mus musculus*). *Horm Behav.* 2002;42:448-460.
  59. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABA<sub>A</sub> receptor: mechanism of action and physiological significance. *Prog Neurobiol.* 1992;38:379-395.
  60. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate  $\gamma$ -aminobutyric acid<sub>A</sub> receptor function through distinct sites. *Brain Res.* 1999;830:72-87.
  61. Wilson MA, Biscardi R. Influence of gender and brain region on neurosteroid modulation of GABA responses in rats. *Life Sci.* 1997;60:1679-1691.
  62. Weihua Z, Lathe R, Warner M, Gustafsson J-A. An endocrine pathway in the prostate, ER $\beta$ , AR,  $5\alpha$ -androstane-3 $\beta$ , 17 $\beta$ -diol, and CYP7B1, regulates prostate growth. *Proc Natl Acad Sci U S A.* 2002;99:13589-13594.
  63. Pak TR, Chung WCJ, Lund TD, Hinds LR, Clay CM, Handa RJ. The androgen metabolite,  $5\alpha$ -androstane-3 $\beta$ , 17 $\beta$ -diol, is a potent modulator of estrogen receptor- $\beta$  mediated gene transcription in neuronal cells. *Endocrinology.* 2005;146:147-155.
  64. Bakker J, Honda S, Harada N, Balhazart J. Restoration of male sexual behavior by adult exogenous estrogens in male aromatase knockout mice. *Horm Behav.* 2004;46:1-10.
  65. Temple JL, Scordalakes EM, Bodo C, Gustafsson J-A, Rissman EF. Lack of functional estrogen receptor  $\beta$  gene disrupts pubertal male sexual behavior. *Horm Behav.* 2003;44:427-434.
  66. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. *N Engl J Med.* 1997;337:91-95.
  67. Carani C, Granata ARM, Rochira V, Caffagni G, Aranda C, Antunez P, Maffei LE. Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadism. *Psychoneuroendocrinology.* 2005;30:413-417.
  68. Bitar MS, Ota M, Linnoila M, Shapiro BH. Modification of gonadectomy-induced increases in brain monoamine metabolism by steroid hormones in male and female rats. *Psychoneuroendocrinology.* 1991;16:547-557.